Vanda Pharmaceuticals
VNDA
178 hedge funds and large institutions have $723M invested in Vanda Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 59 increasing their positions, 63 reducing their positions, and 15 closing their positions.
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
38% more capital invested
Capital invested by funds: $524M → $723M (+$199M)
9% more funds holding
Funds holding: 164 → 178 (+14)
1.2% more ownership
Funds ownership: 99.51% → 100.71% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 63
71% less call options, than puts
Call options by funds: $731K | Put options by funds: $2.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.36M |
| 2 |
BlackRock
New York
|
+$6.46M |
| 3 |
Millennium Management
New York
|
+$5.73M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$4.59M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.43M |
| 2 |
Renaissance Technologies
New York
|
-$4.7M |
| 3 |
SG Americas Securities
New York
|
-$3.54M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.18M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$2.15M |
VNDA Hedge Fund Activity: Q4 2020 in Review
178 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2020, worth a combined $723M — up 38% from $524M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new VNDA positions and 15 closed out — a net gain of 14 holders — while 59 added to existing stakes and 63 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $7.36M. The largest seller was Citadel Advisors, cutting an estimated $8.43M.
- 178 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2020, up from 164 in Q3 2020.
- Funds reported $723M of Vanda Pharmaceuticals stock for Q4 2020, up 38% quarter-over-quarter.
- 29 funds opened new Vanda Pharmaceuticals positions in Q4 2020 and 15 closed out, a net change of +14 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2020 was Morgan Stanley, an estimated $7.36M added.
- The largest Vanda Pharmaceuticals seller in Q4 2020 was Citadel Advisors, an estimated $8.43M sold.
Based on aggregated 13F filings for Q4 2020.